An LRP1-binding motif in cellular prion protein replicates cell-signaling activities of the full-length protein

被引:4
|
作者
Mantuano, Elisabetta [1 ]
Zampieri, Carlotta [1 ]
Azmoon, Pardis [1 ]
Gunner, Cory B. [1 ]
Heye, Kyle R. [1 ]
Gonias, Steven L. [1 ,2 ]
机构
[1] Univ Calif San Diego, Dept Pathol, Sch Med, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA
关键词
RECEPTOR-RELATED PROTEIN-1; HIGH-AFFINITY BINDING; NF-KAPPA-B; PLASMINOGEN-ACTIVATOR; DISEASE PROGRESSION; NEURONAL RECEPTOR; LRP1; MICE; ALPHA-2-MACROGLOBULIN; IDENTIFICATION;
D O I
10.1172/jci.insight.170121
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Low-density lipoprotein receptor-related protein-1 (LRP1) functions as a receptor for nonpathogenic cellular prion protein (PrPC), which is released from cells by ADAM (a disintegrin and metalloproteinase domain) proteases or in extracellular vesicles. This interaction activates cell signaling and attenuates inflammatory responses. We screened 14-mer PrPC-derived peptides and identified a putative LRP1 recognition motif in the PrPC sequence spanning residues 98-111. A synthetic peptide (P3) corresponding to this region replicated the cell-signaling and biological activities of full-length shed PrPC. P3 blocked LPS-elicited cytokine expression in macrophages and microglia and rescued the heightened sensitivity to LPS in mice in which the PrPC gene (Prnp) had been deleted. P3 activated ERK1/2 and induced neurite outgrowth in PC12 cells. The response to P3 required LRP1 and the NMDA receptor and was blocked by the PrPC-specific antibody, POM2. P3 has Lys residues, which are typically necessary for LRP1 binding. Converting Lys100 and Lys103 into Ala eliminated the activity of P3, suggesting that these residues are essential in the LRP1-binding motif. A P3 derivative in which Lys105 and Lys109 were converted into Ala retained activity. We conclude that the biological activities of shed PrPC, attributed to interaction with LRP1, are retained in synthetic peptides, which may be templates for therapeutics development.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Structural Mechanism of Barriers to Interspecies Seeding Transmissibility of Full-Length Prion Protein Amyloid
    Ma, Tao
    Deng, Jing
    Ma, Shaojie
    Zhao, Weijing
    Chang, Ziwei
    Yu, Kunqian
    Yang, Jun
    CHEMBIOCHEM, 2019, 20 (21) : 2757 - 2766
  • [22] Production of a Recombinant Full-Length Prion Protein in a Soluble Form without Refolding or Detergents
    Arii, Yasuhiro
    Oshiro, Satoshi
    Wada, Keita
    Fukuoka, Shin-Ichi
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2011, 75 (06) : 1181 - 1183
  • [23] Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways
    El Moustaine, Driss
    Perrier, Veronique
    Smeller, Laszlo
    Lange, Reinhard
    Torrent, Joan
    FEBS JOURNAL, 2008, 275 (09) : 2021 - 2031
  • [24] Characterization of prion protein (PrP)-derived peptides that discriminate full-length PrPSc from PrPC
    Lau, Anthony L.
    Yam, Alice Y.
    Michelitsch, Melissa M. D.
    Wang, Xuemei
    Gao, Carol
    Goodson, Robert J.
    Shimizu, Robert
    Timoteo, Gulliver
    Hall, John
    Medina-Selby, Angelica
    Coit, Doris
    McCoin, Colin
    Phelps, Bruce
    Wu, Ping
    Hu, Celine
    Chien, David
    Peretz, David
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (28) : 11551 - 11556
  • [25] Induction of antibodies against murine full-length prion protein in wild-type mice
    Koller, MF
    Grau, T
    Christen, P
    JOURNAL OF NEUROIMMUNOLOGY, 2002, 132 (1-2) : 113 - 116
  • [26] A novel copper(II) coordination at His186 in full-length murine prion protein
    Watanabe, Yasuko
    Hiraoka, Wakako
    Igarashi, Manabu
    Ito, Kimihito
    Shimoyama, Yuhei
    Horiuchi, Motohiro
    Yamamoria, Tohru
    Yasui, Hironobu
    Kuwabara, Mikinori
    Inagaki, Fuyuhiko
    Inanami, Osamu
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 394 (03) : 522 - 528
  • [27] Assembly of the full-length recombinant mouse prion protein I.: Formation of soluble oligomers
    Vendrely, C
    Valadié, H
    Bednarova, L
    Cardin, L
    Pasdeloup, M
    Cappadoro, K
    Bednar, J
    Rinaudo, M
    Jamin, M
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2005, 1724 (03): : 355 - 366
  • [28] Cryo-EM structure of an amyloid fibril formed by full-length human prion protein
    Wang, Li-Qiang
    Zhao, Kun
    Yuan, Han-Ye
    Wang, Qiang
    Guan, Zeyuan
    Tao, Jing
    Li, Xiang-Ning
    Sun, Yunpeng
    Yi, Chuan-Wei
    Chen, Jie
    Li, Dan
    Zhang, Delin
    Yin, Ping
    Liu, Cong
    Liang, Yi
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2020, 27 (06) : 598 - +
  • [29] Cryo-EM structure of an amyloid fibril formed by full-length human prion protein
    Li-Qiang Wang
    Kun Zhao
    Han-Ye Yuan
    Qiang Wang
    Zeyuan Guan
    Jing Tao
    Xiang-Ning Li
    Yunpeng Sun
    Chuan-Wei Yi
    Jie Chen
    Dan Li
    Delin Zhang
    Ping Yin
    Cong Liu
    Yi Liang
    Nature Structural & Molecular Biology, 2020, 27 : 598 - 602
  • [30] NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231)
    Riek, R
    Hornemann, S
    Wider, G
    Glockshuber, R
    Wuthrich, K
    FEBS LETTERS, 1997, 413 (02) : 282 - 288